Francis A. Farraye, MD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
Gastroenterology

MD, Albert Einstein College of Medicine
MSc, Harvard School of Public Health




Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville Florida where he co-directs the Inflammatory Bowel Disease Center. Prior to relocating in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center. At Boston University School of Medicine, he was Professor of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master's degree in Epidemiology from the Harvard School of Public Health.

Dr. Farraye's clinical interests are in the care of patients with inflammatory bowel disease. He is currently investigating C. difficile infection in IBD patients, the management and diagnosis of dysplasia and cancer in patients with IBD; social media use and health literacy in IBD patients; hepatitis B vaccination efficacy in patients with IBD; and subclinical hepatic fibrosis in patients with IBD.

A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 450 original scientific manuscripts, book chapters, reviews, and abstracts. He is the series editor for the text Curbside Consultations in Gastroenterology and co-edited the text, Curbside Consultation in Inflammatory Bowel Disease and Gastrointestinal Emergencies. His books for patients include Questions and Answers about Ulcerative Colitis, Questions and Answers about Crohn's Disease and Ulcerative Colitis for Dummies.

Dr. Farraye is a Fellow of the American Society of Gastrointestinal Endoscopy, American Gastroenterological Association and the American College of Gastroenterology. He has served on numerous national and international committees including as a member of the ACG Board of Trustees. He is co-chair of the Crohn's and Colitis Foundation Membership Committee and a member of the Chapter Medical Advisory Committee for the New England Crohn's and Colitis Foundation and a past chairman. The New England Crohn's and Colitis Foundation named Dr. Farraye Humanitarian of the Year in 2003. In 2009, the ACG awarded Dr. Farraye the William Carey Award for service to the college. Dr. Farraye has been recognized as "Top Doctor" in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.

Member
Boston University
Center for Regenerative Medicine


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research



2017 American College of Gastroenterology: Presidential Poster Award
2014 Robert Dawson Evans Award for Quality Improvement and Patient Safety: Committee Member
2013 Institute for Health Care Improvement: Boston University Faculty Development Award: Quality Improvement for Department Chiefs
2013 Boston University School of Medicine: Research Mentor of the Year
2012 Richard Farmer Honorary Lecture: Health Care Maintenance in the IBD Patient
2011 U.S. News and World Report: Top Doctor
2010 Boston Magazine: Best of Boston, Gastroenterology
2010 Boston University School of Management: Boston University Faculty Development Award: Pocket MBA for Physicians
2009 American College of Gastroenterology: William Carey Award
2003 American College of Gastroenterology: Board of Governors Achievement Award
2003 New England Crohn’s and Colitis Foundation of America: Humanitarian of the Year
2002 American College of Gastroenterology: Presidential Poster Award
1999 Harvard Community Health Plan: Key Contribution Award
1998 Harvard Pilgrim Health Care: Ebert Fellowship
1995 Harvard Community Health Plan: Key Contribution Award
1993 Harvard Community Health Plan: Key Contribution Award
1990 Harvard Community Health Plan: Peer Recognition Award
1990 Harvard Community Health Plan: Diamond Award
1990 Harvard Community Health Plan: Key Contribution Award
1986 Harvard Community Health Plan: Peer Recognition Award
1979 American Liver Foundation: Research Fellowship
1979 American Gastroenterological Association: Research Fellowship


A Phase III, Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease
04/01/2009 - 09/30/2017 (PI)
Millennium Pharmaceuticals, Inc.


PUCCINI-Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I
06/23/2014 - 07/01/2017 (Subcontract PI)
Icahn School of Medicine at Mount Sinai Crohns & Colitis Fdn


A Study to Assess the Association of Clinical outcome with serum drug concentration levels and anti-drug antibody in moderately to severely active Crohn's Disease patients treated with Adalimumab prot
08/01/2011 - 07/31/2012 (PI)
Prometheus Laboratories, Inc.


PROCUREMENT OF BLOOD SAMPLES FROM IBD, GI CONTROLS AND HEALTHY VOLUN TEER SUBJECTS FOR USE IN THE
01/01/2011 - 12/31/2011 (PI)
Prometheus Laboratories, Inc.


C13006, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Modera
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.


C13007, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizuamb (MLN0002) in Patients with Modera
04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.


A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effects of Certolizumab Pegol in Patients with Moderate to Severe Crohn’s Disease (COSPAR I)
11/06/2006 - 11/05/2008 (PI)
UCB Pharma, Inc.

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Infliximab
12/08/2006 - 06/07/2007 (PI)
Abbott Laboratories

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate for the Induction of Clinical Response in Patients with Crohn’s Disease
10/06/2005 - 10/05/2006 (PI)
Synta Pharmaceuticals Corporation

An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
11/04/2004 - 07/19/2005 (PI)
GlaxoSmithKline, Inc.

Showing 10 of 14 results. Show All Results

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Invest to Invest…
10/03/2016 - 10/02/2019 (PI)
Celgene Corporation

EH-5151- Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin / Protein Isola…
07/25/2016 - 07/24/2019 (PI)
Entera Health, Inc.

IBD-600 Registry
09/19/2018 - 03/31/2019 (PI)
Corrona, LLC

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Ac…
10/08/2015 - 09/30/2018 (PI)
Takeda Pharmaceuticals

Sample Collection Study to Evaluate DNA Markers in Subjects with Inflammatory Bowel Disease (IBD)…
12/22/2014 - 10/10/2017 (PI)
Exact Sciences

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease:OCEANIA Study
12/12/2014 - 06/30/2017 (PI)
Exact Sciences

A Prospective, Randomized,Double Blinded, Placebo-Controlled Phase II Clinical Study of Trichuris…
05/01/2014 - 12/31/2015 (PI)
Duke University NIH-NIAID

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease
12/20/2012 - 09/01/2015 (PI)
Cubist Pharmaceuticals Inc

Methotrexate Response in Treatment of UC - MERIT-UC
08/15/2011 - 01/31/2014 (PI)
University of North Carolina NIH-NIDDK

PIANO: Pregnancy in Inflammatory Bowel Disease & Neonatal Outcomes
07/01/2010 - 12/31/2011 (PI)
Univ of California, San Francisco Crohn's & Colitis Fo

Showing 10 of 12 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Paulsen MR, Patel NR, Sulis C, Farraye FA, Bhat S. Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists. J Pharm Pract. 2020 Sep 17; 897190020958261. PMID: 32938309
     
  2. Bhat S, Farraye FA, Moss AC. Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic. Am J Gastroenterol. 2020 09; 115(9):1532-1533.View Related Profiles. PMID: 32694291
     
  3. Caldera F, Hayney MS, Farraye FA. Vaccination in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2020 09; 115(9):1356-1361. PMID: 32744811
     
  4. Moktan V, Jonica E, Li Z, Hata DJ, Farraye FA. C. difficile and the Patient with Inflammatory Bowel Disease: A Testing Dilemma. Dig Dis Sci. 2020 Aug 16. PMID: 32803461
     
  5. Green ME, Brahmbhatt B, Baumgarten D, Krishna M, Stocchi L, Farraye FA. Meckel's Diverticulum Masquerading as Crohn Disease. Inflamm Bowel Dis. 2020 Jul 21. PMID: 32692353
     
  6. Guo L, Rohde J, Farraye FA. Stigma and Disclosure in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Jun 18; 26(7):1010-1016. PMID: 32556190
     
  7. Grossberg LB, Farraye FA, Papamichael K, Cheifetz AS, Feuerstein JD. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis. 2020 Jun 18; 26(7):e59-e61. PMID: 32304571
     
  8. Chen Y, Yu Q, Farraye FA, Kochhar GS, Bernstein CN, Navaneethan U, Wu K, Zhong J, Schwartz DA, Wu H, Zheng JJ, Iacucci M, Kiran RP, Shen B. Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice. Intest Res. 2020 Jun 02. PMID: 32475088
     
  9. Qazi T, Smith A, Alexander M, Hammer D, Wu T, Auerbach S, Noronha A, Wasan S, Jones E, Weinberg J, Farraye FA. Disparities in Objective Sleep Quality as Assessed Through Wrist Actigraphy in Minority Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 May 25.View Related Profiles. PMID: 32448906
     
  10. Kröner PT, Lee A, Farraye FA. Respiratory Tract Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 May 25. PMID: 32448912
     
Showing 10 of 353 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 352 publications over 32 distinct years, with a maximum of 26 publications in 2010

YearPublications
19871
19883
19892
19901
19912
19921
19944
19964
19972
19983
19998
20005
20018
200211
200314
200415
200514
200614
20076
200818
200916
201026
201120
20129
201323
201417
201517
201624
201719
201810
201917
202018


11 GI Leaders To Know In March

Becker's GI & Endoscopy 4/1/2019
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Colon Cancer
Colon Polyps
Crohn’s Disease
Dysplasia
Ileal Pouch Anal Anastomosis
Inflammatory Bowel Disease
Ulcerative Colitis
Vitamin D

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

85 E. Concord St
Boston MA 02118
Google Map


Farraye's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department